Rhythm Pharmaceuticals (RYTM) Operating Margin (2021 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Operating Margin of 87.11% for Q1 2026, up 5662.0% year-over-year from 1.51% in Q1 2025, and down 5.97% quarter-over-quarter from 82.2% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Operating Margin (2021 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Operating Margin for 6 consecutive years, with 87.11% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 5662.0% year-over-year to 87.11%; the TTM figure through Mar 2026 stood at 90.89% (up 3524.0% YoY), while the FY2025 annual figure was 101.19%, up 10284.0% from the prior year.
- Operating Margin slipped to 87.11% in Q1 2026 per RYTM's latest filing, from 82.2% in the prior quarter.
- Across five years, Operating Margin topped out at 523.15% in Q4 2022 and bottomed at 3517.42% in Q1 2022.
- Historically, Operating Margin has averaged 405.41% across 5 years, with a median of 143.73% in 2025.
- Annual changes were most pronounced in 2022 — Operating Margin jumped 9476258 bps — and 2023, when it tumbled 69343 bps.
- Rhythm Pharmaceuticals' Operating Margin stood at 523.15% in 2022, then tumbled by 133 bps to 170.28% in 2023, then jumped by 42 bps to 98.63% in 2024, then gained by 17 bps to 82.2% in 2025, then fell by 6 bps to 87.11% in 2026.
- Business Quant data shows RYTM's Operating Margin at 87.11% in Q1 2026, 82.2% in Q4 2025, and 102.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -68.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.14% |
| Mar 31, 2026 | -87.11% |
| Dec 31, 2025 | -82.20% |
| Sep 30, 2025 | -102.64% |
| Jun 30, 2025 | -93.39% |
| Mar 31, 2025 | -143.73% |
| Dec 31, 2024 | -98.63% |
| Sep 30, 2024 | -131.98% |
| Jun 30, 2024 | -139.20% |
| Mar 31, 2024 | -538.71% |
| Dec 31, 2023 | -170.28% |
| Sep 30, 2023 | -195.31% |
| Jun 30, 2023 | -242.46% |
| Mar 31, 2023 | -458.03% |
| Dec 31, 2022 | 523.15% |
| Sep 30, 2022 | -916.60% |
| Jun 30, 2022 | -497.42% |
| Mar 31, 2022 | -3,517.42% |
| Dec 31, 2021 | -2,806.22% |
| Sep 30, 2021 | -4,303.50% |